Left Ventricular Hypertrophy Clinical Trial
Official title:
acTive scrEening of cArdiac aMyloidosis in the Caribbean's
The frequency of cardiac amyloidosis among patients presenting with a so-called left ventricular hypertrophy remains unknown. This problem is especially relevant in the Caribbean's, where an amyloidosis-prone mutation of transthyretin gene might be frequent.
Cardiac amyloidosis is a very poorly known disease, in its frequency, its mechanisms, its
treatment. This lack of knowledge is a major limitation to the improvement, indispensable, of
the care of the patients. In clinical routine, particularly in West Indies-Guyana, cardiac
amyloidosis is a disease poorly identified, whose management remains to be optimized.
Concordant observations suggest that the frequency of the disease could be significant in the
Antilles-Guyana: aging of the population, high frequency of an amyloidogenic mutation
(Val122Il mutation of the transthyretin gene) found in 4% of the Afro-American population,
recent identification in Martinique by a neurology team of a new founding mutation of the
transthyretin gene that may cause the disease.
These elements justified the setting up of a multidisciplinary group whose objective is to
contribute to the improvement of screening, treatment, and follow-up of patients with cardiac
amyloidosis.
An identical diagnostic algorithm will be followed in all centers. Therapeutic management
will be left to the discretion of the health care teams, who will be communicated regularly,
the latest management recommendations.
A frequency of 30% is expected and will be assessed with a power of 80% and an alpha risk of
0.05. Quantitative and qualitative data will be described as usual. Differences between
groups will be assessed with parametric or non-parametric tests.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Completed |
NCT03332745 -
Mechanism of Decompensation Evaluation - Aortic Stenosis
|
||
Completed |
NCT01951404 -
Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study
|
Phase 4 | |
Terminated |
NCT01188369 -
Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy
|
Phase 4 | |
Completed |
NCT00344903 -
Dallas Heart Study 2: Return Clinic Visit for the Dallas Heart Study Cohort
|
N/A | |
Completed |
NCT00518479 -
Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression
|
N/A | |
Completed |
NCT00001632 -
Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease
|
N/A | |
Completed |
NCT00001534 -
Long Term Effects of Enalapril and Losartan on Genetic Heart Disease
|
N/A | |
Suspended |
NCT03193073 -
Anemia Correction and Fibroblast Growth Factor 23 Levels in Chronic Kidney Disease , and Renal Transplant Patient
|
N/A | |
Enrolling by invitation |
NCT05903313 -
A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
|
||
Recruiting |
NCT05646056 -
A Noninterventional, Single-Center Feasibility Study to Evaluate Measures of Heart Failure Risk
|
||
Completed |
NCT01455974 -
The Effects of Lowering Dialysate Sodium in Hypertensive Hemodialysis Patients
|
N/A | |
Active, not recruiting |
NCT00418041 -
Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study)
|
N/A | |
Completed |
NCT00602004 -
Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan
|
N/A | |
Completed |
NCT00219141 -
Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension
|
Phase 3 | |
Completed |
NCT03666351 -
Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease
|
Phase 4 | |
Recruiting |
NCT05730309 -
Point-of-care Ultrasound and Treatment Disparities for Left Ventricular Hypertrophy
|
N/A | |
Not yet recruiting |
NCT04022330 -
Protective Monocytes and Macrophages to Limit Decompensation and Heart Damaging
|
N/A | |
Recruiting |
NCT06169358 -
Screening Patients With Fabry Disease in Patients With Hypertrophic Cardiomyopathy or Left Ventricular Hypertrophy
|
||
Recruiting |
NCT05179668 -
SGLT2 Inhibition in Hemodialysis
|
Phase 2 |